Background

Primary chemotherapy for patients with AML leads to high complete response rates in younger patients with significantly lower rates in older patients as well as those with leukemia secondary to antecedent myelodysplastic syndromes (MDS) or previous chemoradiotherapy. For patients who achieve complete remission (CR), response durability is also significantly lower in older patients or those with a clinically apparent secondary onset (1-7). AML features in older patients and those with previous...

References

Introduction the history of arsenic trioxide in cancer therapy. Oncologist 2001 6 1,2. 2. Kwong YL, Todd D. Delicious poison arsenic trioxide for the treatment of leukemia. Blood 1997 89 3487,3488. 3. Aronson SM. Arsenic and old myths. Rhode Island Med 1994 77 233,234. 4. Gallagher RE. Arsenic new life for an old potion. N Engl J Med 1998 339 1389-1391. 5. Forkner C, Scott T. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1938 97 3-5. 6. Sun H, Ma L, Hu X,...